http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009088819-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f34119b232d292c72e632b62008eca90
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36007
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-36
filingDate 2008-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d06d380c3070cd7616e030f0c040a8a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97ff726d0d959729b3328635a1c75521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f50fa2a677598853932db69e959bcca3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f622f768b9fdd574084fcc9e238d41a9
publicationDate 2009-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2009088819-A1
titleOfInvention Gastric electrical stimulation with multi-site stimulation anti-desensitization feature
abstract The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019001139-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11090491-B2
priorityDate 2007-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004059393-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004147976-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6115635-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5292344-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005131493-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005065575-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005149142-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6449511-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7343201-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5188104-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5231988-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005137643-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002107476-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006173507-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006095088-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5690691-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007255333-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7242983-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002198470-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004230255-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6026326-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002072780-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002161414-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5540730-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465611170
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163876867

Total number of triples: 42.